{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125337","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.517498+00:00","generated_at":"2026-05-30T02:04:50.090102+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Erasca Q3 2024 net loss $31.2M; cash $463.3M; positive Phase 1b naporafenib data","bullets":["Net loss of $31.2M ($0.11/share) vs $30.4M ($0.20/share) in Q3 2023.","Cash, equivalents, and marketable securities $463.3M; expected to fund operations into H1 2027.","R&D expenses $27.6M (up from $25.2M YoY) driven by clinical and preclinical activities.","Positive preliminary Phase 1b SEACRAFT-1 data for naporafenib + trametinib in NRASm melanoma bolsters Phase 3 SEACRAFT-2 conviction.","IND filings on track: ERAS-4001 pan-KRAS inhibitor Q1 2025, ERAS-0015 pan-RAS glue H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125337","json":"https://secwatch.observer/filing/0000950170-24-125337.json","markdown":"https://secwatch.observer/filing/0000950170-24-125337.md","text":"https://secwatch.observer/filing/0000950170-24-125337.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017024125337/0000950170-24-125337-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017024125337/eras-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:04:50.090102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}